Insights

Home » Insights » Insights Intercept Blood System
    08/2018- Economics

    INTERCEPT Blood System further expands with  the TS  multidose set (video)

    In Europe, 40% of all platelet concentrates undergo either bacterial screening or pathogen inactivation. This percentage may increase even more in 2018 as major European countries are currently taking action to mitigate the risk of septic transfusion reactions and emerging pathogens. 


    08/2018- Cerus

    Let us do something about it!

    In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.


    08/2018- Hospital News

    Clinical efficiency and patient safety of INTERCEPT Blood System

    The INTERCEPT Blood System for platelets has demonstrated clinical efficacy for treating and preventing bleeding in clinical trials and in routine use.1

    While many studies were performed in haematology/oncology patients, this study focused on the clinical efficacy during massive transfusion.


    07/2018- Economics

    The economics of Double Dose Buffy Coat Platelets

    For blood centres seeking a cost-effective way to implement INTERCEPT pathogen inactivation, double dose buffy coat platelet production may offer a solution.

    What is a double dose buffy coat platelet unit?

    A platelet concentrate with sufficient platelet count to result in 2 therapeutic doses after pathogen inactivation with the INTERCEPT Blood System.

    The double dose buffy coat platelet...


    07/2018- Hospital News

    INTERCEPT Blood System  for massively transfused patients

    Large Austrian Medical Centre publishes study results on component utilization and patient safety after adoption of platelet pathogen inactivation.

    The Medical University Hospital in Innsbruck has evaluated the influence of the INTERCEPT™ Blood System for platelets on component utilization and patient safety. The effectiveness of conventional vs. INTERCEPT™-treated platelets was analyzed...


    07/2018- Cerus

    2 million Swiss francs to  develop a whole blood PI system in Africa

    The Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa.